TY - JOUR
T1 - Conversion to resection post radioembolization in patients with HCC
T2 - recommendations from a multidisciplinary working group
AU - Baker, Talia
AU - Tabrizian, Parissa
AU - Zendejas, Ivan
AU - Gamblin, Thomas Clark
AU - Kazimi, Marwan
AU - Boudjema, Karim
AU - Geller, David
AU - Salem, Riad
N1 - Funding Information:
Under the direction of all authors, medical writing assistance was provided by Adrienne Halupa, PhD, of SAGE Medica Inc, and Alexandra Greenberg-Worisek, PhD, MPH, of Boston Scientific Corporation. This assistance was supported by BTG/Boston Scientific Corporation through provision of an educational grant to the University of Chicago.
Publisher Copyright:
© 2022 International Hepato-Pancreato-Biliary Association Inc.
PY - 2022/7
Y1 - 2022/7
N2 - Background: Transarterial radioembolization (TARE) with yttrium-90 (90Y) glass microspheres is an efficacious option for converting appropriately selected patients with borderline-resectable hepatocellular carcinoma (HCC) to surgical candidacy. Methods: In 2018 and 2019, a diverse multidisciplinary group of surgical and interventional experts with experience using 90Y for downstaging and bridging to liver transplant convened to review peer-reviewed literature and personal experience in the use of 90Y to convert borderline resectable liver cancer patients to surgical candidacy. The working group included surgical oncologists specializing in liver cancer, liver transplant surgeons with experience in complex hepatobiliary surgery, and interventional radiologists with experience using 90Y. Results: This document presents expert recommendations based upon the group's experience and consensus. Conclusions: By combining related evidence from the literature with expert experiences with TARE in surgical candidates, these recommendations aim to demonstrate the safety, efficacy, and feasibility of TARE in converting borderline-resectable patients to surgical options. The document also addresses the concerns about potential complications associated with TARE during the surgical intervention.
AB - Background: Transarterial radioembolization (TARE) with yttrium-90 (90Y) glass microspheres is an efficacious option for converting appropriately selected patients with borderline-resectable hepatocellular carcinoma (HCC) to surgical candidacy. Methods: In 2018 and 2019, a diverse multidisciplinary group of surgical and interventional experts with experience using 90Y for downstaging and bridging to liver transplant convened to review peer-reviewed literature and personal experience in the use of 90Y to convert borderline resectable liver cancer patients to surgical candidacy. The working group included surgical oncologists specializing in liver cancer, liver transplant surgeons with experience in complex hepatobiliary surgery, and interventional radiologists with experience using 90Y. Results: This document presents expert recommendations based upon the group's experience and consensus. Conclusions: By combining related evidence from the literature with expert experiences with TARE in surgical candidates, these recommendations aim to demonstrate the safety, efficacy, and feasibility of TARE in converting borderline-resectable patients to surgical options. The document also addresses the concerns about potential complications associated with TARE during the surgical intervention.
UR - http://www.scopus.com/inward/record.url?scp=85122536501&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122536501&partnerID=8YFLogxK
U2 - 10.1016/j.hpb.2021.12.013
DO - 10.1016/j.hpb.2021.12.013
M3 - Article
C2 - 35012876
AN - SCOPUS:85122536501
SN - 1365-182X
VL - 24
SP - 1007
EP - 1018
JO - HPB
JF - HPB
IS - 7
ER -
